The objective of this study is to evaluate LDL-C reduction over time among individuals initiating alirocumab 150 mg compared with inclisiran in routine clinical practice. The study will leverage observational data reflective of routine care and apply contemporary methods in target trial emulation and causal inference to estimate comparative treatment effects.

Inclusion Criteria:

• Participants initiating alirocumab 150 mg or inclisiran.
• Participants with at least once LDL-C measurement during 365 days before index.
• Participants who continuously enrolled in medical and pharmacy benefits for at least 365 days pre index.

Exclusion Criteria:

• Participants with unknown sex, geographic region, or insurance type, and age < 18 years at index.
• Participants with exposure to evolocumab before index.

The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.

Adults (>= 18 years) initiating alirocumab 150 mg or inclisiran among adults eligible for proprotein convertase subtilisin/kexin type 9 (PCSK9) -targeting therapy in routine practice: from January 2016 to July 2024.

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org